FDA grants priority review for Apalutamide in non-metastatic castration-resistant prostate cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Janssen Biotech Inc. said FDA has granted priority review designation for the New Drug Application for apalutamide, an investigational, next-generation oral androgen receptor inhibitor for the treatment of men with non-metastatic castration-resistant prostate cancer. Currently, there are no FDA-approved treatments for patients with non-metastatic CRPC.

The Priority Review designation means FDA’s goal is to take action on an application within six months of receipt, compared to 10 months for Standard Review. The FDA has assigned a Prescription Drug User Fee Act target date of April 2018 to render a decision on the apalutamide application.

The NDA submission for apalutamide, which was completed on Oct. 10, 2017, was based on phase III data from the pivotal ARN-509-003 (SPARTAN) clinical trial, which assessed the safety and efficacy of apalutamide versus placebo in men with non-metastatic CRPC who have a rapidly rising prostate specific antigen despite receiving continuous androgen deprivation therapy.

The primary endpoint of this study was metastasis-free survival. MFS is the time from randomization to first evidence of confirmed metastasis, or time to death. The SPARTAN study results have been accepted for oral presentation at the ASCO Genitourinary Cancers Symposium Feb. 8, 2018, in San Francisco.

Apalutamide is an investigational, next-generation oral androgn receptor inhibitor that inhibits the action of androgen in prostate cancer cells, and prevents binding of androgen to the androgen receptor, and translocation of the androgen receptor to the nucleus of the cancer cell.

Table of Contents

YOU MAY BE INTERESTED IN

Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.
The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login